ImmuneOncia aims to develop immuno-oncology therapeutics

to transform the standard of care in cancer treatment

  • IR/PR
  • Disclosures

Disclosures

Submission Date Disclosure Title Author
2026-05-15 [Corrected description]Quarterly Report (2026.03) 이뮨온시아
2026-05-15 Quarterly Report (2026.03) 이뮨온시아
2026-05-15 Results of Subscription (Voluntary Disclosure) 이뮨온시아
2026-05-11 [Corrected description]Prospectus 이뮨온시아
2026-05-11 [Conditions for issuance finalized]Registration Statement (Equity securities) 이뮨온시아
2026-05-11 [Corrected description]Decision on Capital Increase with Consideration 이뮨온시아
2026-05-08 Final Issue Price of Rights Offering 이뮨온시아
2026-04-30 Report on status of specific securities, etc. owned by executives and major shareholders 유한양행
2026-04-30 Report on significant holdings of stocks, etc. (General) 유한양행
2026-04-22 Report on status of specific securities, etc. owned by executives and major shareholders 유한양행
1 2 3 4 5